To me this looks good, but I wonder what the market will make of this: “An uneven profit profile for CSL is expected for the first and second half results, due to the seasonality of the influenza business and the timing of expenses – particularly research and development,” Mr. Perreault added.
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$262.28 |
Change
6.970(2.73%) |
Mkt cap ! $126.9B | |||
| Open | High | Low | Value | Volume |
| $258.12 | $263.22 | $257.91 | $103.3M | 395.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 72 | $262.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $262.29 | 39 | 6 |
View Market Depth
| Last trade - 12.07pm 22/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |